SRPK1 is a determinant of chemoresistance to Docetaxel in prostate cancer
Docetaxel is a major therapeutic option for advanced prostate cancer, but the development of acquired resistance substantially limits its clinical efficacy. Although multiple mechanisms have been implicated in docetaxel resistance, the upstream regulatory pathways coordinating these phenotypes remain incompletely understood. Here, we investigated the role of serine/arginine-rich protein kinase 1…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
